IL17A and rheumatoid arthritis: According to DrugBank information from June 11, 2024, inhibitors of some of the mentioned cytokines (Anakinra (IL-1 receptor antagonist), Secukinumab, and Ixekizumab (antibodies against IL-17A)) are approved for RA treatment [11].